Regulatory Takeda’s first-in-class narcolepsy drug claims FDA approval PharmaphorumTakeda's orexin agonist Orzeyful is the first drug approved in the US that can treat the "full range" of narcolepsy type 1 symptoms, says the FDA.NeuroscienceRead full story pharminent August 6, 2026 (Last updated: August 8, 2026) Pharmaphorum Takeda’s orexin agonist Orzeyful is the first drug approved in the US that can treat the “full range” of narcolepsy type 1 symptoms, says the FDA. Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Eli Lilly Smashes Q2 Estimates, Raises 2026 Guidance to $85–$87B on GLP-1 SurgeNext: FDA Approves Moderna’s mFlusiva, the First mRNA-Based Seasonal Flu Vaccine Related Stories Regulatory Replimune rebounds to win FDA approval of melanoma drug pharminent August 6, 2026 Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026
